CTOs on the Move

Singlera Genomics

www.singleraoncology.com

 
Singlera Genomics Inc., a fast growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu (CTO). The company currently has an R&D center in La Jolla, California, and a business and clinical operation site in Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. In the past decade, Professor Gao, Professor Zhang and Dr. Liu have made outstanding achievements in their respective ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Singlera Genomics raised $20M on 08/22/2016
Singlera Genomics raised $60M on 03/27/2018
Singlera Genomics raised $150M on 12/15/2020

Similar Companies

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies.

DNA Diagnostics Center

DNA Diagnostics Center is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Biotech Associates

Southern Biotech Associates is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.